A Phase 1 interventional study of GBT021601 in Sickle Cell Disease, sponsored by Pfizer. Completed at 3 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-06-10.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Anemia, Sickle Cell by Pfizer — 1 open to participants now, 1 under way, 1 of them phase 3. Anemia, Sickle Cell · Pfizer.
Among the 32 studies in Anemia, Sickle Cell by Pfizer, this one is the 23rd largest by enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2021, is one of 10 in phase 1, and was the 19th registered.
1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.
Browse Anemia, Sickle Cell studies →1 of the 32 studies in Anemia, Sickle Cell by Pfizer is open now, in 7 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Brazil, India and 4 more countries
Ages 12+
By country, each count listing its studies:
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 5 · Phase 3 11 · Phase 4 3
First in 2014; this study’s year is marked. 5 started in 2021.
This study's enrollment of 6 is below the median of 40 across 769 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 52 across the 27 interventional studies, 216 across the 3 observational. Of the 28 that completed or were terminated, 19 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 32 studies in Anemia, Sickle Cell by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK), and pharmacodynamics (i.e., how the body absorbs, distributes, breaks down, and excretes) of GBT021601, a hemoglobin S (HbS) polymerization inhibitor, in participants with SCD, following single and multiple ascending doses.
This is an open-label intrapatient single dose followed by a multiple dose escalation study in at least six (6) participants with SCD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Refer to Study Description
Drug: GBT021601
Refer to Study Description
Drug: GBT021601
Tablets and capsules which contain GBT021601 drug substance
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An adverse event (AE) was any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. A treatment-emergent AE (TEAE) was an AE that occurs or worsens during the on-treatment period defined as the time from the first dose of study drug through minimum of 56 days after last dose of study treatment. A Serious Adverse Event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening experience (immediate risk of death); required inpatient hospitalization or prolongation if existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect; was considered an important medical event. TEAEs and SAEs were reported for both Sickle Cell Disease (SCD) and non-SCD related events, in this outcome measure.
Time frame: From first dose of study drug (Day 1) to at least 56 days after last dose of study drug (up to a maximum of 316 days)
Number of Participants With Clinically Significant Physical Examination Findings
Physical examination included were general appearance, head, ears, eyes, nose, throat, neck, skin, cardiovascular system, respiratory system, gastrointestinal system, musculoskeletal system, lymph nodes, and nervous system. Clinically significant physical examination abnormalities were considered as adverse events based on investigator's discretion.
Time frame: Baseline (Day 1) up to at least 56 days after last dose of study drug (up to a maximum of 316 days)
Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters
Laboratory parameters included hematology(hemoglobin,hematocrit,red blood cell count,platelet count,white blood cell count,total neutrophils,eosinophils,monocytes,basophils,lymphocytes);blood chemistry(blood urea,nitrogen, creatinine,glucose,calcium,sodium,potassium,chloride,total bicarbonate,aspartate aminotransferase,alanine aminotransferase,total bilirubin,alkaline phosphatase,uric acid albumin,total protein);urinalysis(decimal logarithm of reciprocal of hydrogen ion activity \[pH\], glucose, protein, blood,ketones, microscopy\[urine tested positive for blood or protein\]),urine drug screening:cannabinoids,amphetamines,methamphetamines,opiates,methadone,cocaine,benzodiazepines,phencyclidine,barbiturates,alcohol breath test. Hemoximetry RBC deformability,dense cells test; erythropoietin,follicle stimulating hormone,pregnancy test,Serology panel for HIV 1/2 antibody,Hepatitis A, B and C,SARS CoV-2.Clinical significance of any parameter was determined at the investigator's discretion.
Time frame: Baseline (Day 1) up to at least 56 days after last dose of study drug (up to a maximum of 316 days)
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
Vital signs assessments included were systolic and diastolic blood pressure, heart rate, respiratory rate and body temperature. These measurements were taken after the participants had rested for at least 5 minutes in the supine position. Any clinically significant abnormal vital sign assessment required at least one repeat measurement. Clinical significance of any parameter was determined based on investigator's discretion.
Time frame: Baseline (Day 1) up to at least 56 days after last dose of study drug (up to a maximum of 316 days)
Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG)
ECG values included here were Heart rate (HR), PR, QRS, QT, and QTcF intervals, interpretation of the tracings (eg, rhythm, presence of arrhythmia or conduction defects, any evidence of myocardial ischemia/infarction, or ST segment, T-wave, and U-wave abnormalities). Abnormal and clinically significant 12-lead ECG included QT interval corrected for heart rate according to Fridericia's formula (QTcF) \> 450 millisecond (ms), QRS interval \>= 120 ms, PR interval \> 220 ms, based on the average of triplicated ECG, assessed at Screening and Day-1. If any of these test results were out of range, then the test could be repeated once (in triplicate).
Time frame: Baseline (Day 1) up to at least 56 days after last dose of study drug (up to a maximum of 316 days)
Maximum GBT021601 Concentration (Cmax) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A
Cmax was defined as the peak concentration observed directly from the experimental data without any interpolation.
Time frame: Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1
Maximum GBT021601 Concentration (Cmax) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part B
Cmax was defined as the peak concentration observed directly from the experimental data without any interpolation.
Time frame: Pre-dose, 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 56, 63, 70, 77, 84, 91, 98, 105, 112
Maximum GBT021601 Concentration (Cmax) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part C
Cmax was defined as the peak concentration observed directly from the experimental data without any interpolation.
Time frame: Pre-dose on Day 1, 14, 28, 42 and 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 28 and 42
Minimum GBT021601 Concentration (Cmin) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part B
Cmin was defined as the lowest concentration observed directly from the experimental data without any interpolation.
Time frame: Pre-dose, 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 56, 63, 70, 77, 84, 91, 98, 105, 112
Minimum GBT021601 Concentration (Cmin) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part C
Cmin was defined as the lowest concentration observed directly from the experimental data without any interpolation.
Time frame: Pre-dose on Day 1, 14, 28, 42 and 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 28 and 42
Time to Attain Maximum Serum Concentration (Tmax) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A
Maximum observed concentration was defined as the peak concentration observed directly from the experimental data without any interpolation. The time to the maximum observed concentration was defined as the time corresponding to Cmax.
Time frame: Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1
Area Under the Concentration Time Curve From Time Zero to the Next Dose (AUC0-tau) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A
AUC0-tau was defined from time 0 to time of the last quantifiable concentration and was calculated using the linear or logarithmic trapezoid rule. AUCtau was calculated by using hours\*microgram per milliliter (hr\*mcg)/mL.
Time frame: Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1
Area Under the Serum Concentration Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A
AUCinf was defined as the area calculated by linear/log trapezoid rule from time 0 to infinity with the area extrapolated from the last quantifiable concentration to infinity.
Time frame: Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1
Area Under the Concentration Time Curve From Time Zero up to Time 24 Hours (AUC 0-24) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A
AUC0-24 was defined as the area under the free plasma concentration time curve from time 0 to 24 hours post-dose.
Time frame: Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs post-dose on Day 1
Apparent Oral Clearance (CL/F) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A
CL/F was a quantitative measure of the rate at which a drug substance was removed from the blood. It was calculated as dose of GBT021601 by AUC from time 0 to infinity.
Time frame: Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1
Terminal Elimination Half-Life (t1/2) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A
t1/2 was the time measured for the plasma concentration to decrease by one half.
Time frame: Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1
Apparent Volume of Distribution (Vz/F) in Plasma, Whole Blood and Red Blood Cells (RBCs): Part A
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F was determined based on the fraction absorbed.
Time frame: Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1
Percentage Hemoglobin Occupancy
Percentage hemoglobin occupancy (%Hb Occupancy) refers to the proportion of hemoglobin molecules within red blood cells that were bound to study drug (GBT021601). Cmin and Cmax values was used to calculate %Hb occupancy: %Hb Occupancy = GBT021601\*RBC per Mean Corpuscular Hemoglobin Concentration (MCHC).
Time frame: Part A: Pre-dose,0.25,0.5,1,2,4, 6,8,12,24,36,48,72,168,336,504,672,1008 hrs on Day 1; Part B: Pre-dose,0.25 to 1,2 to 4 hrs post-dose on Day 56,63,70,77,84,91,98,105,112; Part C:Pre-dose on Day 1,14,28,42 and 0.25 to 1, 2 to 4 hrs post-dose on Day 28,42
Plasma Concentrations Versus Time Summary of GBT021601: Part A
The plasma concentration versus time summary was measured by the amount of specific substance in the bloodstream over the specified timepoint.
Time frame: Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1
Plasma Concentrations Versus Time Summary of GBT021601: Part B
The plasma concentration versus time summary was measured by the amount of specific substance in the bloodstream over the specified timepoint.
Time frame: Pre-dose, 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 56, 63, 70, 77, 84, 91, 98, 105, 112, 140,168, 196, 218
Plasma Concentrations Versus Time Summary of GBT021601: Part C
The plasma concentration versus time summary was measured by the amount of specific substance in the bloodstream over the specified timepoint.
Time frame: Pre-dose on Day 1, 14, 28, 42 and 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 28, 42, 70, 98
Whole Blood Concentrations Versus Time Summary of GBT021601: Part A
The whole blood concentration versus time summary was measured to find concentration of various components in whole blood that changed over a specified period. This helped to monitor the dynamics of blood components such as hemoglobin levels, hematocrit, or glucose concentration over time.
Time frame: Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1
Whole Blood Concentrations Versus Time Summary of GBT021601: Part B
The whole blood concentration versus time summary was measured to find concentration of various components in whole blood that changed over a specified period. This helped to monitor the dynamics of blood components such as hemoglobin levels, hematocrit, or glucose concentration over time.
Time frame: Pre-dose, 0.25 hr to 1 hr, 2 to 4 hrs, post-dose on Day 56, 63, 70, 77, 84, 91, 98, 105, 112, 140,168, 196, 218
Whole Blood Concentrations Versus Time Summary of GBT021601: Part C
The whole blood concentration versus time summary was measured to find concentration of various components in whole blood that changed over a specified period. This helped to monitor the dynamics of blood components such as hemoglobin levels, hematocrit, or glucose concentration over time.
Time frame: Pre-dose on Day 1, 14, 28, 42 and 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 28, 42, 70, 98
Red Blood Cell Concentrations Versus Time Summary of GBT021601: Part A
The RBC concentration versus time summary was measured to identify quantity of RBC in a sample of blood over a specified duration. This analysis helped monitor RBC level over time.
Time frame: Pre-dose, 0.25 hour (hr), 0.5 hr, 1 hr, 2 hrs, 4 hrs, 6 hrs, 8 hrs,12 hrs, 24 hrs, 36 hrs, 48 hrs, 72 hrs, 168 hrs, 336 hrs, 504 hrs, 672 hrs, 1008 hrs post-dose on Day 1
Red Blood Cell Concentrations Versus Time Summary of GBT021601: Part B
The RBC concentration versus time summary was measured to identify quantity of RBC in a sample of blood over a specified duration. This analysis helped monitor RBC level over time.
Time frame: Pre-dose, 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 56, 63, 70, 77, 84, 91, 98, 105, 112, 140,168, 196, 218
Red Blood Cell Concentrations Versus Time Summary of GBT021601: Part C
The RBC concentration versus time summary involved tracking a quantity of RBC in a sample of blood over a specified duration. This analysis helped to monitor RBC level over time.
Time frame: Pre-dose on Day 1, 14, 28, 42 and 0.25 hr to 1 hr, 2 to 4 hrs post-dose on Day 28, 42, 70, 98
| Milestone | Part A: Single Dose Period | Part B: Multiple Ascending- Dose Period | Part C: Extended Treatment Period |
|---|---|---|---|
| Started | 6 | 0 | 0 |
| Completed | 6 | 0 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Part A: Single Dose Period | Part B: Multiple Ascending- Dose Period | Part C: Extended Treatment Period |
|---|---|---|---|
| Started | 0 | 6 | 0 |
| Completed | 0 | 5 | 0 |
| Not completed | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Milestone | Part A: Single Dose Period | Part B: Multiple Ascending- Dose Period | Part C: Extended Treatment Period |
|---|---|---|---|
| Started | 0 | 0 | 4 |
| Completed | 0 | 0 | 3 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 1 |
An adverse event (AE) was any untoward medical occurrence in a study participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. A treatment-emergent AE (TEAE) was an AE that occurs or worsens during the on-treatment period defined as the time from the first dose of study drug through minimum of 56 days after last dose of study treatment. A Serious Adverse Event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening experience (immediate risk of death); required inpatient hospitalization or prolongation if existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect; was considered an important medical event. TEAEs and SAEs were reported for both Sickle Cell Disease (SCD) and non-SCD related events, in this outcome measure.
| Participants | Part A: Single Dose Period | Part B: Multiple Ascending- Dose Period | Part C: Extended Treatment Period |
|---|---|---|---|
| TEAEs: SCD Related | 1 | 3 | 1 |
| SAEs: SCD Related | 0 | 2 | 0 |
| TEAEs: Non-SCD Related | 5 | 5 | 3 |
| SAEs: Non-SCD Related | 0 | 0 | 0 |
Physical examination included were general appearance, head, ears, eyes, nose, throat, neck, skin, cardiovascular system, respiratory system, gastrointestinal system, musculoskeletal system, lymph nodes, and nervous system. Clinically significant physical examination abnormalities were considered as adverse events based on investigator's discretion.
| Participants | Part A: Single Dose Period | Part B: Multiple Ascending- Dose Period | Part C: Extended Treatment Period |
|---|---|---|---|
| Number of Participants With Clinically Significant Physical Examination Findings | 0 | 0 | 0 |
Laboratory parameters included hematology(hemoglobin,hematocrit,red blood cell count,platelet count,white blood cell count,total neutrophils,eosinophils,monocytes,basophils,lymphocytes);blood chemistry(blood urea,nitrogen, creatinine,glucose,calcium,sodium,potassium,chloride,total bicarbonate,aspartate aminotransferase,alanine aminotransferase,total bilirubin,alkaline phosphatase,uric acid albumin,total protein);urinalysis(decimal logarithm of reciprocal of hydrogen ion activity \[pH\], glucose, protein, blood,ketones, microscopy\[urine tested positive for blood or protein\]),urine drug screening:cannabinoids,amphetamines,methamphetamines,opiates,methadone,cocaine,benzodiazepines,phencyclidine,barbiturates,alcohol breath test. Hemoximetry RBC deformability,dense cells test; erythropoietin,follicle stimulating hormone,pregnancy test,Serology panel for HIV 1/2 antibody,Hepatitis A, B and C,SARS CoV-2.Clinical significance of any parameter was determined at the investigator's discretion.
| Participants | Part A: Single Dose Period | Part B: Multiple Ascending- Dose Period | Part C: Extended Treatment Period |
|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters | 1 | 0 | 0 |
Vital signs assessments included were systolic and diastolic blood pressure, heart rate, respiratory rate and body temperature. These measurements were taken after the participants had rested for at least 5 minutes in the supine position. Any clinically significant abnormal vital sign assessment required at least one repeat measurement. Clinical significance of any parameter was determined based on investigator's discretion.
| Participants | Part A: Single Dose Period | Part B: Multiple Ascending- Dose Period | Part C: Extended Treatment Period |
|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Vital Signs | 0 | 0 | 0 |
ECG values included here were Heart rate (HR), PR, QRS, QT, and QTcF intervals, interpretation of the tracings (eg, rhythm, presence of arrhythmia or conduction defects, any evidence of myocardial ischemia/infarction, or ST segment, T-wave, and U-wave abnormalities). Abnormal and clinically significant 12-lead ECG included QT interval corrected for heart rate according to Fridericia's formula (QTcF) \> 450 millisecond (ms), QRS interval \>= 120 ms, PR interval \> 220 ms, based on the average of triplicated ECG, assessed at Screening and Day-1. If any of these test results were out of range, then the test could be repeated once (in triplicate).
| Participants | Part A: Single Dose Period | Part B: Multiple Ascending- Dose Period | Part C: Extended Treatment Period |
|---|---|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) | 1 | 0 | 0 |
Cmax was defined as the peak concentration observed directly from the experimental data without any interpolation.
| Microgram per milliliter (mcg/mL) | Part A: Single Dose Period |
|---|---|
| Plasma | 1.01 ± 20.81 |
| Whole Blood | 16.2 ± 25.90 |
| RBC concentration | 69.2 ± 28.63 |
Cmax was defined as the peak concentration observed directly from the experimental data without any interpolation.
| mcg/mL | Part B: Multiple Ascending- Dose Period |
|---|---|
| Plasma- Day 56 | 2.46 ± 15.27 |
| Plasma- Day 63 | 1.28 ± 18.54 |
| Plasma- Day 70 | 1.54 ± 32.36 |
| Plasma- Day 77 | 1.17 ± 22.44 |
| Plasma- Day 84 | 1.17 ± 19.75 |
| Plasma- Day 91 | 5.15 ± 19.32 |
| Plasma- Day 98 | 2.77 ± 16.41 |
| Plasma- Day 105 | 2.96 ± 19.79 |
| Plasma- Day 112 | 3.22 ± 15.50 |
| Whole Blood- Day 56 | 40.9 ± 25.31 |
| Whole Blood- Day 63 | 85.5 ± 40.91 |
| Whole Blood- Day 70 | 80.3 ± 37.07 |
| Whole Blood- Day 77 | 87.1 ± 41.84 |
| Whole Blood- Day 84 | 89.1 ± 52.79 |
| Whole Blood- Day 91 | 136 ± 41.37 |
| Whole Blood- Day 98 | 201 ± 33.19 |
| Whole Blood- Day 105 | 194 ± 44.14 |
| Whole Blood- Day 112 | 200 ± 31.58 |
| RBC concentration- Day 56 | 169 ± 25.28 |
| RBC concentration- Day 63 | 366 ± 38.19 |
| RBC concentration- Day 70 | 309 ± 38.95 |
| RBC concentration- Day 77 | 337 ± 43.45 |
| RBC concentration- Day 84 | 345 ± 50.80 |
| RBC concentration- Day 91 | 522 ± 35.93 |
| RBC concentration- Day 98 | 788 ± 25.66 |
| RBC concentration- Day 105 | 748 ± 27.21 |
| RBC concentration- Day 112 | 670 ± 33.48 |
Cmax was defined as the peak concentration observed directly from the experimental data without any interpolation.
| mcg/mL | Part C: Extended Treatment Period |
|---|---|
| Plasma - Day 28 | 2.66 ± 78.79 |
| Plasma - Day 42 | 4.25 ± 81.86 |
| Whole Blood - Day 28 | 166 ± 126.31 |
| Whole Blood - Day 42 | 175 ± 141.04 |
| RBC concentration - Day 28 | 531 ± 105.76 |
| RBC concentration - Day 42 | 540 ± 125.43 |
Cmin was defined as the lowest concentration observed directly from the experimental data without any interpolation.
| mcg/mL | Part B: Multiple Ascending- Dose Period |
|---|---|
| Plasma- Day 63 | 0.97 ± 27.41 |
| Plasma- Day 70 | 0.98 ± 22.18 |
| Plasma- Day 77 | 0.90 ± 20.38 |
| Plasma- Day 84 | 0.884 ± 21.58 |
| Plasma- Day 91 | 0.90 ± 30.51 |
| Plasma- Day 98 | 1.94 ± 24.77 |
| Plasma- Day 105 | 1.84 ± 27.55 |
| Plasma- Day 112 | 2.03 ± 24.43 |
| Whole Blood- Day 63 | 62.6 ± 42.01 |
| Whole Blood- Day 70 | 72.8 ± 36.26 |
| Whole Blood- Day 77 | 77.4 ± 45.27 |
| Whole Blood- Day 84 | 70.8 ± 67.54 |
| Whole Blood- Day 91 | 76.5 ± 49.02 |
| Whole Blood- Day 98 | 172 ± 43.11 |
| Whole Blood- Day 105 | 161 ± 45.00 |
| Whole Blood- Day 112 | 182 ± 31.55 |
| RBC concentration- Day 63 | 267 ± 41.68 |
| RBC concentration- Day 70 | 280 ± 38.56 |
| RBC concentration- Day 77 | 299 ± 46.55 |
| RBC concentration- Day 84 | 274 ± 65.32 |
| RBC concentration- Day 91 | 299 ± 43.50 |
| RBC concentration- Day 98 | 674 ± 34.28 |
| RBC concentration- Day 105 | 621 ± 26.23 |
| RBC concentration- Day 112 | 620 ± 34.72 |
Cmin was defined as the lowest concentration observed directly from the experimental data without any interpolation.
| mcg/mL | Part C: Extended Treatment Period |
|---|---|
| Plasma - Day 28 | 1.54 ± 220.43 |
| Plasma - Day 42 | 1.99 ± 264.95 |
| Whole Blood - Day 28 | 122 ± 211.47 |
| Whole Blood - Day 42 | 140 ± 217.11 |
| RBC concentration - Day 28 | 392 ± 174.41 |
| RBC concentration - Day 42 | 433 ± 187.77 |
Maximum observed concentration was defined as the peak concentration observed directly from the experimental data without any interpolation. The time to the maximum observed concentration was defined as the time corresponding to Cmax.
| Hours | Part A: Single Dose Period |
|---|---|
| Plasma | 1.50 (1.00 to 2.02) |
| Whole Blood | 8.06 (6.00 to 35.92) |
| RBC concentration | 8.06 (6.00 to 35.92) |
AUC0-tau was defined from time 0 to time of the last quantifiable concentration and was calculated using the linear or logarithmic trapezoid rule. AUCtau was calculated by using hours\*microgram per milliliter (hr\*mcg)/mL.
| (hr*mcg)/mL | Part A: Single Dose Period |
|---|---|
| Plasma | 67.102 ± 13.91 |
| Whole Blood | 4597.8 ± 27.07 |
| RBC concentration | 19627.6 ± 30.93 |
AUCinf was defined as the area calculated by linear/log trapezoid rule from time 0 to infinity with the area extrapolated from the last quantifiable concentration to infinity.
| (hr*mcg)/mL | Part A: Single Dose Period |
|---|---|
| Plasma | 72.03 ± 16.43 |
| Whole Blood | 4914.50 ± 29.55 |
| RBC concentration | 234.08 ± 13.95 |
AUC0-24 was defined as the area under the free plasma concentration time curve from time 0 to 24 hours post-dose.
| (hr*mcg)/mL | Part A: Single Dose Period |
|---|---|
| Plasma | 7.94 ± 12.11 |
| Whole Blood | 322.0 ± 25.28 |
| RBC concentration | 1363.3 ± 29.90 |
CL/F was a quantitative measure of the rate at which a drug substance was removed from the blood. It was calculated as dose of GBT021601 by AUC from time 0 to infinity.
| Liter per hour | Part A: Single Dose Period |
|---|---|
| Plasma | 1.39 ± 16.43 |
| Whole Blood | 0.02 ± 29.55 |
| RBC concentration | 0.004 ± 33.36 |
t1/2 was the time measured for the plasma concentration to decrease by one half.
| hr | Part A: Single Dose Period |
|---|---|
| Plasma | 236.191 (187.44 to 313.49) |
| Whole Blood | 230.908 (207.80 to 303.05) |
| RBC concentration | 231.272 (206.58 to 302.82) |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F was determined based on the fraction absorbed.
| Liter | Part A: Single Dose Period |
|---|---|
| Plasma | 480 ± 13.30 |
| Whole Blood | 6.87 ± 22.56 |
| RBC concentration | 1.61 ± 26.23 |
Percentage hemoglobin occupancy (%Hb Occupancy) refers to the proportion of hemoglobin molecules within red blood cells that were bound to study drug (GBT021601). Cmin and Cmax values was used to calculate %Hb occupancy: %Hb Occupancy = GBT021601\*RBC per Mean Corpuscular Hemoglobin Concentration (MCHC).
| Percentage of Hemoglobin | Part A: Single Dose Period | Part B: Multiple Ascending- Dose Period | Part C: Extended Treatment Period |
|---|---|---|---|
| Part A: Cmax- Day 1 | 3.36 ± 0.86 | — | — |
| Part B: Cmax- Day 56 | — | 8.15 ± 1.89 | — |
| Part B: Cmax - Day 63 | — | 18.15 ± 5.96 | — |
| Part B: Cmin- Day 63 | — | 13.40 ± 4.71 | — |
| Part B: Cmax- Day 70 | — | 15.50 ± 5.11 | — |
| Part B: Cmin- Day 70 | — | 14.03 ± 4.69 | — |
| Part B: Cmax- Day 77 | — | 17.03 ± 6.00 | — |
| Part B: Cmin- Day 77 | — | 15.25 ± 5.54 | — |
| Part B: Cmax- Day 84 | — | 17.66 ± 7.75 | — |
| Part B: Cmin- Day 84 | — | 14.57 ± 7.29 | — |
| Part B: Cmax- Day 91 | — | 25.71 ± 7.92 | — |
| Part B: Cmin- Day 91 | — | 15.02 ± 5.85 | — |
| Part B: Cmax- Day 98 | — | 38.00 ± 9.05 | — |
| Part B: Cmin- Day 98 | — | 33.04 ± 9.31 | — |
| Part B: Cmax- Day 105 | — | 36.11 ± 9.14 | — |
| Part B: Cmin- Day 105 | — | 29.89 ± 7.21 | — |
| Part B: Cmax- Day 112 | — | 32.68 ± 9.33 | — |
| Part B: Cmin- Day 112 | — | 30.32 ± 8.92 | — |
| Part C: Cmax- Day 28 | — | — | 31.45 ± 17.97 |
| Part C: Cmin- Day 28 | — | — | 26.54 ± 16.96 |
| Part C: Cmax- Day 42 | — | — | 33.13 ± 19.12 |
| Part C: Cmin- Day 42 | — | — | 29.46 ± 18.09 |
The plasma concentration versus time summary was measured by the amount of specific substance in the bloodstream over the specified timepoint.
| mcg/mL | Part A: Single Dose Period |
|---|---|
| Pre-dose | 0 ± 0 |
| 0.25 hour | 0.145 ± 0.137 |
| 0.5 hour | 0.617 ± 0.281 |
| 1 hour | 0.910 ± 0.312 |
| 2 hours | 0.821 ± 0.202 |
| 4 hours | 0.498 ± 0.150 |
| 6 hours | 0.350 ± 0.100 |
| 8 hours | 0.279 ± 0.737 |
| 12 hours | 0.228 ± 0.040 |
| 24 hours | 0.257 ± 0.120 |
| 36 hours | 0.333 ± 0.286 |
| 48 hours | 0.183 ± 0.067 |
| 72 hours | 0.138 ± 0.019 |
| 168 hours | 0.124 ± 0.020 |
| 336 hours | 0.0786 ± 0.016 |
| 504 hours | 0.047 ± 0.016 |
| 672 hours | 0.029 ± 0.137 |
| 1008 hours | 0.013 ± 0.007 |
The plasma concentration versus time summary was measured by the amount of specific substance in the bloodstream over the specified timepoint.
| mcg/mL | Part B: Multiple Ascending- Dose Period |
|---|---|
| Day 56: Pre-dose | 0.143 ± 0.351 |
| Day 56 :0.25-1 hour | 1.163 ± 1.165 |
| Day 56: 2-4 hours | 2.345 ± 0.3129 |
| Day 63: Pre-dose | 1.015 ± 0.240 |
| Day 63: 0.25-1 hour | 1.148 ± 0.268 |
| Day 63: 2-4 hours | 1.250 ± 0.210 |
| Day 70: Pre-dose | 1.003 ± 0.211 |
| Day 70: 0.25-1 hour | 1.376 ± 0.653 |
| Day 70: 2-4 hours | 1.415 ± 0.262 |
| Day 77: Pre-dose | 0.937 ± 0.151 |
| Day 77: 0.25-1 hour | 1.103 ± 0.318 |
| Day 77: 2-4 hours | 1.173 ± 0.233 |
| Day 84: Pre-dose | 0.918 ± 0.176 |
| Day 84 :0.25-1 hour | 1.085 ± 0.284 |
| Day 84: 2-4 hours | 1.097 ± 0.205 |
| Day 91: Pre-dose | 0.941 ± 0.278 |
| Day 91; 0.25-1 hour | 3.019 ± 2.225 |
| Day 91: 2-4 hours | 4.990 ± 0.635 |
| Day 98: Pre-dose | 2.118 ± 0.687 |
| Day 98: 0.25-1 hour | 2.242 ± 0.398 |
| Day 98: 2-4 hours | 2.580 ± 0.53933 |
| Day 105: Pre-dose | 1.945 ± 0.570 |
| Day 105: 0.25-1 hour | 2.147 ± 0.470 |
| Day 105: 2-4 hours | 2.953 ± 0.642 |
| Day 112 :Predose | 2.095 ± 0.242 |
| Day 112: 0.25-1 hour | 2.748 ± 0.824 |
| Day 112: 2-4 hours | 2.905 ± 0.688 |
| Day 140: 2-4 hours | 0.225 ± 0.0516 |
| Day 168: 2-4 hours | 0.042 ± 0.026 |
| Day 196: 2-4 hours | 0.005 ± 0.005 |
| Day 218: 2-4 hours | 0.000 ± 0.001 |
The plasma concentration versus time summary was measured by the amount of specific substance in the bloodstream over the specified timepoint.
| mcg/mL | Part C: Extended Treatment Period |
|---|---|
| Day 28: Pre-dose | 2.448 ± 1.786 |
| Day 28: 4 hours | 2.991 ± 1.476 |
| Day 42: Pre-dose | 3.621 ± 2.929 |
| Day 42: 0.25-1 hour | 4.285 ± 2.785 |
| Day 42: 2-4 hours | 4.485 ± 2.308 |
| Day 70: 2-4 hours | 0.364 ± 0.101 |
| Day 98: 2-4 hours | 0.034 ± 0.011 |
The whole blood concentration versus time summary was measured to find concentration of various components in whole blood that changed over a specified period. This helped to monitor the dynamics of blood components such as hemoglobin levels, hematocrit, or glucose concentration over time.
| mcg/mL | Part A: Single Dose Period |
|---|---|
| Pre-dose | 0 ± 0 |
| 0.25 hour | 1.034 ± 0.876 |
| 0.5 hour | 4.775 ± 2.470 |
| 1 hour | 8.745 ± 3.833 |
| 2 hours | 12.710 ± 3.190 |
| 4 hours | 14.07 ± 2.917 |
| 6 hours | 14.44 ± 2.980 |
| 8 hours | 14.42 ± 2.861 |
| 12 hours | 14.45 ± 3.811 |
| 24 hours | 14.42 ± 3.220 |
| 36 hours | 15.41 ± 4.220 |
| 48 hours | 13.14 ± 2.895 |
| 72 hours | 12.42 ± 3.193 |
| 168 hours | 9.847 ± 2.562 |
| 336 hours | 5.282 ± 1.283 |
| 504 hours | 3.870 ± 1.071 |
| 672 hours | 2.138 ± 1.283 |
| 1008 hours | 0.943 ± 0.729 |
The whole blood concentration versus time summary was measured to find concentration of various components in whole blood that changed over a specified period. This helped to monitor the dynamics of blood components such as hemoglobin levels, hematocrit, or glucose concentration over time.
| mcg/mL | Part B: Multiple Ascending- Dose Period |
|---|---|
| Day 56: Pre-dose | 0.071 ± 0.085 |
| Day 56: 0.25-1 hour | 13.20 ± 13.601 |
| Day 56: 2-4 hours | 41.23 ± 10.318 |
| Day 63: Pre-dose | 74.32 ± 30.266 |
| Day 63: 0.25-1 hour | 88.23 ± 33.335 |
| Day 63: 2- 4 hours | 74.87 ± 19.748 |
| Day 70: Pre-dose | 78.28 ± 24.403 |
| Day 70: 0.25-1 hour | 81.00 ± 22.709 |
| Day 70: 2-4 hours | 81.25 ± 25.669 |
| Day 77: Pre-dose | 86.22 ± 30.703 |
| Day 77: 0.25-1 hour | 87.33 ± 27.507 |
| Day 77: 2- 4 hours | 88.68 ± 29.043 |
| Day 84: Predose | 87.77 ± 43.076 |
| Day 84 :0.25-1 hour | 88.97 ± 42.685 |
| Day 84: 2-4 hours | 92.05 ± 36.530 |
| Day 91: Pre-dose | 85.07 ± 32.859 |
| Day 91; 0.25-1 hour | 102.4 ± 52.161 |
| Day 91: 2-4 hours | 144.1 ± 47.113 |
| Day 98: Pre-dose | 195.8 ± 61.979 |
| Day 98: 0.25-1 hour | 188.8 ± 61.802 |
| Day 98: 2-4 hours | 198.8 ± 49.301 |
| Day 105: Pre-dose | 189.8 ± 56.672 |
| Day 105: 0.25-1 hour | 178.9 ± 66.612 |
| Day 105: 2-4 hours | 203.3 ± 74.923 |
| Day 112: Pre-dose | 195.0 ± 59.117 |
| Day 112: 0.25-1 hour | 200.5 ± 57.263 |
| Day 112: 2-4 hours | 198.5 ± 59.248 |
| Day 140: 2-4 hours | 29.32 ± 20.149 |
| Day 168: 2-4 hours | 3.082 ± 2.137 |
| Day 196: 2-4 hours | 0.561 ± 0.560 |
| Day 218: 2-4 hours | 0.108 ± 0.109 |
The whole blood concentration versus time summary was measured to find concentration of various components in whole blood that changed over a specified period. This helped to monitor the dynamics of blood components such as hemoglobin levels, hematocrit, or glucose concentration over time.
| mcg/mL | Part C: Extended Treatment Period |
|---|---|
| Day 28: Pre-dose | 202.2 ± 136.32 |
| Day 28: 4 hours | 193.6 ± 106.16 |
| Day 42: Pre-dose | 214.8 ± 131.21 |
| Day 42: 0.25-1 hour | 213.5 ± 119.79 |
| Day 42: 2- 4 hours | 229.9 ± 132.21 |
| Day 70: 2-4 hours | 33.50 ± 2.553 |
| Day 98: 2-4 hours | 3.310 ± 0.826 |
The RBC concentration versus time summary was measured to identify quantity of RBC in a sample of blood over a specified duration. This analysis helped monitor RBC level over time.
| mcg/mL | Part A: Single Dose Period |
|---|---|
| Pre-dose | 0 ± 0 |
| 0.25 hour | 3.989 ± 3.314 |
| 0.5 hour | 18.68 ± 10.413 |
| 1 hour | 34.84 ± 16.282 |
| 2 hours | 52.51 ± 14.931 |
| 4 hours | 59.50 ± 14.281 |
| 6 hours | 61.72 ± 15.356 |
| 8 hours | 61.68 ± 13.932 |
| 12 hours | 62.24 ± 18.340 |
| 24 hours | 61.92 ± 16.283 |
| 36 hours | 65.62 ± 18.780 |
| 48 hours | 56.60 ± 14.463 |
| 72 hours | 53.68 ± 15.728 |
| 168 hours | 42.41 ± 12.260 |
| 336 hours | 22.73 ± 6.316 |
| 504 hours | 16.65 ± 4.931 |
| 672 hours | 9.207 ± 5.652 |
| 1008 hours | 4.073 ± 3.186 |
The RBC concentration versus time summary was measured to identify quantity of RBC in a sample of blood over a specified duration. This analysis helped monitor RBC level over time.
| mcg/mL | Part B: Multiple Ascending- Dose Period |
|---|---|
| Day 56: Pre-dose | 0.120 ± 0.134 |
| Day 56 :0.25-1 hour | 52.57 ± 53.388 |
| Day 56: 2-4 hours | 170.8 ± 45.616 |
| Day 63: Pre-dose | 317.4 ± 126.93 |
| Day 63: 0.25-1 hour | 375.4 ± 134.89 |
| Day 63: 2-4 hours | 318.6 ± 83.313 |
| Day 70: Pre-dose | 304.7 ± 105.71 |
| Day 70: 0.25-1 hour | 313.9 ± 97.320 |
| Day 70: 2-4 hours | 314.7 ± 106.95 |
| Day 77: Pre-dose | 335.9 ± 130.15 |
| Day 77: 0.25-1 hour | 340.1 ± 118.67 |
| Day 77: 2-4 hours | 343.8 ± 120.89 |
| Day 84: Pre-dose | 338.6 ± 169.41 |
| Day 84 :0.25-1 hour | 344.7 ± 170.26 |
| Day 84: 2-4 hours | 356.0 ± 144.12 |
| Day 91: Pre-dose | 329.0 ± 124.33 |
| Day 91; 0.25-1 hour | 392.6 ± 197.92 |
| Day 91: 2-4 hours | 547.7 ± 173.83 |
| Day 98: Pre-dose | 753.5 ± 207.85 |
| Day 98: 0.25-1 hour | 726.2 ± 215.42 |
| Day 98: 2-4 hours | 768.9 ± 164.84 |
| Day 105: Pre-dose | 711.7 ± 148.81 |
| Day 105: 0.25-1 hour | 662.4 ± 190.38 |
| Day 105: 2-4 hours | 752.8 ± 222.08 |
| Day 112: Predose | 705.6 ± 209.26 |
| Day 112: 0.25-1 hour | 674.3 ± 201.56 |
| Day 112: 2-4 hours | 666.7 ± 206.56 |
| Day 140: 2-4 hours | 120.8 ± 83.588 |
| Day 168: 2-4 hours | 14.97 ± 9.339 |
| Day 196: 2-4 hours | 2.326 ± 2.226 |
| Day 218: 2-4 hours | 0.850 ± 0.539 |
The RBC concentration versus time summary involved tracking a quantity of RBC in a sample of blood over a specified duration. This analysis helped to monitor RBC level over time.
| mcg/mL | Part C: Extended Treatment Period |
|---|---|
| Day 28: Pre-dose | 621.3 ± 428.95 |
| Day 28: 4 hours | 594.4 ± 319.62 |
| Day 42: Pre-dose | 642.4 ± 396.97 |
| Day 42: 0.25-1 hour | 639.8 ± 361.11 |
| Day 42: 2-4 hours | 691.1 ± 404.73 |
| Day 70: 2-4 hours | 117.9 ± 20.028 |
| Day 98: 2-4 hours | 12.74 ± 3.256 |
Collected over From baseline (Day 1) up to at least 56 days after last dose of study drug (for a maximum of 316 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Single Dose Period (SCD Related) | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Part B: Multiple Ascending- Dose Period (SCD Related) | 0/6 (0%) | 2/6 (33.3%) | 2/6 (33.3%) |
| Part C: Extended Treatment Period (SCD Related) | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Part A: Single Dose Period (Non-SCD Related) | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Part B: Multiple Ascending- Dose Period (Non-SCD Related) | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Part C: Extended Treatment Period (Non-SCD Related) | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Event | Part A: Single Dose Period (SCD Related) | Part B: Multiple Ascending- Dose Period (SCD Related) | Part C: Extended Treatment Period (SCD Related) | Part A: Single Dose Period (Non-SCD Related) | Part B: Multiple Ascending- Dose Period (Non-SCD Related) | Part C: Extended Treatment Period (Non-SCD Related) |
|---|---|---|---|---|---|---|
| Sickle cell anaemia with crisisBlood and lymphatic system disorders | 0/6 | 2/6 | 0/4 | 0/6 | 0/6 | 0/4 |
| Event | Part A: Single Dose Period (SCD Related) | Part B: Multiple Ascending- Dose Period (SCD Related) | Part C: Extended Treatment Period (SCD Related) | Part A: Single Dose Period (Non-SCD Related) | Part B: Multiple Ascending- Dose Period (Non-SCD Related) | Part C: Extended Treatment Period (Non-SCD Related) |
|---|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 0/6 | 0/6 | 0/4 | 0/6 | 2/6 | 0/4 |
| DiarrhoeaGastrointestinal disorders | 0/6 | 0/6 | 0/4 | 0/6 | 2/6 | 0/4 |
| Sickle cell anaemia with crisisBlood and lymphatic system disorders | 1/6 | 2/6 | 1/4 | 0/6 | 0/6 | 0/4 |
| Abdominal painGastrointestinal disorders | 0/6 | 0/6 | 0/4 | 0/6 | 0/6 | 1/4 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/6 | 0/6 | 0/4 | 0/6 | 1/6 | 1/4 |
| Back painMusculoskeletal and connective tissue disorders | 0/6 | 0/6 | 0/4 | 0/6 | 0/6 | 1/4 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/6 | 0/6 | 0/4 | 0/6 | 0/6 | 1/4 |
| HeadacheNervous system disorders | 0/6 | 0/6 | 0/4 | 1/6 | 0/6 | 1/4 |
| AnaemiaBlood and lymphatic system disorders | 0/6 | 0/6 | 0/4 | 0/6 | 1/6 | 0/4 |
| ThrombocytosisBlood and lymphatic system disorders | 0/6 | 0/6 | 0/4 | 1/6 | 0/6 | 0/4 |
Safety population was defined as all participants who received any amount of study drug (GBT021601).
| Age, Continuous(Years) | Overall Study |
|---|---|
| Mean | 20.2 ± 2.23 |
| Sex: Female, Male(Participants) | Overall Study |
|---|---|
| Female | 2 |
| Male | 4 |
| Ethnicity (NIH/OMB)(Participants) | Overall Study |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 5 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Overall Study |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 5 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from May 2021 to primary completion in Dec 2022, 18 months.
Results were first posted in Jun 2024, 1 year 6 months after primary completion.
Of 28 industry-sponsored phase 1 interventional studies under Anemia, Sickle Cell, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's 18 months is below that.
Counting every sponsor, half of 58 studies reached it within 36 months; a quarter within 18 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Osivelotor